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A B S T R A C TObjectives: Economic evaluations of interventions to prevent and
control sexually transmitted infections such as Chlamydia trachomatis
are increasingly required to present their outcomes in terms of
quality-adjusted life-years using preference-based measurements of
relevant health states. The objectives of this study were to critically
evaluate how published cost-effectiveness studies have conceptual-
ized and valued health states associated with chlamydia and to
examine the primary evidence available to inform health state utility
values (HSUVs). Methods: A systematic review was conducted, with
searches of six electronic databases up to December 2012. Data on
study characteristics, methods, and main results were extracted by
using a standard template. Results: Nineteen economic evaluations
of relevant interventions were included. Individual studies considered
different health states and assigned different values and durations.
Eleven studies cited the same source for HSUVs. Only ﬁve primary
studies valued relevant health states. The methods and viewpoints
adopted varied, and different values for health states were generated.see front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.10.005
s@bham.ac.uk.
ndence to: Tracy E. Roberts, Health Economics Un
T, UK.Conclusions: Limitations in the information available about HSUVs
associated with chlamydia and its complications have implications
for the robustness of economic evaluations in this area. None
of the primary studies could be used without reservation to inform
cost-effectiveness analyses in the United Kingdom. Future debate
should consider appropriate methods for valuing health states for
infectious diseases, because recommended approaches may not
be suitable. Unless we adequately tackle the challenges asso-
ciated with measuring and valuing health-related quality of life for
patients with chlamydia and other infectious diseases, evaluating
the cost-effectiveness of interventions in this area will remain
problematic.
Keywords: chlamydia, economic evaluation, health states, infectious
diseases, valuation.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Evidence about the cost-effectiveness of health care interven-
tions is an integral requirement for key decision-making bodies
in many countries, including the United Kingdom [1,2]. Many
decision-making bodies require interventions to be assessed in
terms of their cost per quality-adjusted life-year (QALY), which
combines improvements in health-related quality of life (HRQOL)
and life expectancy with people’s relative preferences for health
states [3]. Preference-based health state utility values (HSUVs)
assign a value to the health states experienced by the patient. A
value of “1” represents full health, and a value of “0” indicates a
health state equivalent to being dead. Utility values can be
generated directly or indirectly. Standard gamble or time trade-
off (TTO) techniques generate direct valuations from patients or
the public on the basis of their experiences or hypotheticalscenarios. Indirect methods typically use an instrument to
measure HRQOL and then apply preference values obtained from
surveys of the general public [4]. The conceptualization of health
states and the application of HSUVs can have a major effect on
results of cost-effectiveness studies [5,6]. There is a growing body
of literature with estimates for HSUVs for a wide range of
conditions that can be used to inform cost-effectiveness studies
when reliance on primary data is not possible or valid [7]. There are
many disease areas, however, in which HSUVs are less widely
available, and there are subsets of populations for whom
preference-basedmeasurements of HRQOL are less well researched
or in whom such measurement is perceived as more difﬁcult [8,9].
Cost-effectiveness studies inﬂuence decisions about funding
for particular interventions, and so their methodological quality
is extremely important [10]. While there has been a growing
literature aimed at improving the standard of economicociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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less attention has been devoted to the methods involved in
identifying and applying HSUVs [6,11]. The conceptualization
and structure of a decision-analytic model determines how
health states are deﬁned and represented, and so disease proc-
esses must be represented appropriately [12].
As with all model input parameters estimated from secondary
sources, a systematic review of the literature should be done to
identify, assess, and synthesize information to estimate HSUVs
and uncertainty needs to be fully reported and examined
[11,13,14]. Two sets of criteria are relevant to the assessment
and selection of HSUVs [5]. The ﬁrst relates to the descriptive
systems, methods, and sources used to generate the values; in
the United Kingdom, these are likely to be assessed against
recommendations from the National Institute for Health and
Care Excellence (NICE) [15,16]. The second relates to the relevance
of the population in the utility study to that in the economic
evaluation, in terms of factors such as the condition, its severity,
and patients’ age proﬁles.
Many investigators have studied the cost-effectiveness of
interventions to prevent, control, and treat Chlamydia trachomatis
[17–19]. Chlamydia is the most common bacterial sexually trans-
mitted infection (STI) worldwide [20] and in the United Kingdom
[21], with an estimated prevalence of 3% to 6% in sexually active
15- to 25-year-olds in the general population [22–24]. Chlamydia
ﬁrst infects the lower genital tract, causing cervicitis in women
and urethritis in men, both of which are usually asymptomatic [25]
and last more than a year, on average, if untreated [26]. Infection
can clear spontaneously or can ascend to the upper genital tract at
any time [27], causing symptoms of pelvic inﬂammatory disease
(PID) in 10% to 15% of women [28,29] and epididymo-orchitis in a
smaller proportion of men [25]. Symptoms of PID include lower
abdominal pain and pain during sexual intercourse. Fallopian tube
inﬂammation can, rarely, cause tubo-ovarian abscess. Tubal scar-
ring and blockage can cause chronic pelvic pain, ectopic preg-
nancy, and tubal factor infertility [30]. There is uncertainty about
the incidence, duration, and timing of late complications because
contraception can delay their diagnosis for many years and
chlamydia is only one cause [31]. Chlamydial infection during
pregnancy is associated with premature labor, and neonatal
infection can cause conjunctivitis and pneumonia [32,33].
Screening for chlamydia infection in asymptomatic sexually
active young adults is recommended because of the frequency of
asymptomatic infections, the severity of complications, and the
easy availability of both reliable diagnostic tests and efﬁcacious
antibiotic treatment. If decision makers are to interpret cost-
effectiveness analyses of interventions to prevent and control
chlamydia appropriately, their HSUVs must reﬂect the effect on
those experiencing complications.
The Challenges Associated with Valuing Health States for
Chlamydia
We believe that there are several challenges to the identiﬁcation,
assessment, and utilization of appropriate information on HSUVs
for use in economic evaluations of STIs such as chlamydia. First,
there are considerations relating to the actual state of infection
itself. Chlamydia, like many STIs, is often asymptomatic, and so
most infected individuals do not experience any apparent detri-
ment to their quality of life at the time of infection [34], even
though the average duration of untreated infection is more than 1
year and people are infectious throughout [26]. There is qualita-
tive evidence, however, to suggest that being tested for chlamy-
dia and receiving a positive diagnosis does have an impact on
quality of life, particularly for women [35,36]. Second, owing to
the obvious ethical and practical issues associated with studying
untreated chlamydia, there is considerable uncertainty about thenatural history of infection and disease, including the timing,
incidence, and duration of complications [37,38] and rates and
risks associated with reinfection [31].
Third, chlamydia is only one cause of many of the late
sequelae associated with the infection. There is limited evidence
about whether the etiology of conditions such as chronic pelvic
pain or infertility affects HRQOL [39–41]. Qualitative evidence
suggests that the stigma associated with STIs mediates the
experience of being in the health state [35], and so HRQOL might
differ between women with infertility secondary to an STI and
those with cancer, for example. Fourth, the health states asso-
ciated with chlamydial disease last for different amounts of time;
tubal infertility might be permanent, while the infection itself
and some of its sequelae, such as PID and ectopic pregnancy, are
temporary states [42,43]. Temporary health states might involve
different methods for valuation, and there is a need to consider
how preferences for temporary and permanent states are com-
bined [44]. Fifth, the sequelae associated with chlamydia some-
times occur many years after the initial infection [37], and so
issues of time preference are likely to have an effect on the
valuation of the health states [45,46]. Finally, the burdens asso-
ciated with the disease are asymmetrical; although both men and
women experience infection, the main complications associated
with chlamydia affect women of reproductive age [31], but
fertility problems can affect others besides the woman herself.
This might affect the conceptualization of health outcomes and
decisions about whose preferences should count [47,48].
The objectives of this study were to identify and critically
evaluate economic evaluations that included QALYs as an out-
come measure to identify how health states have been concep-
tualized and valued within cost-effectiveness studies. Primary
studies that valued relevant health states were also located to
examine the data that could be used to inform cost-effectiveness
studies incorporating HSUVs for chlamydia and its sequelae.Methods
We conducted a systematic review following UK Centre for
Review and Dissemination guidelines for methods and Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines for reporting, where appropriate [49,50].
Inclusion Criteria
Articles were included if they met the following criteria: the
participants were men or women with, or at risk of, sexually
transmitted chlamydia or its sequelae; the intervention (for
economic evaluations) was any medical procedure to prevent,
control, or treat chlamydia infection or its sequelae; the main
outcomes were either cost per QALY (for economic evaluations)
or the measurement and valuation of health states associated
with chlamydial infection and its sequelae. We excluded articles
that were wholly concerned with conditions affecting the pelvic
area and not likely to be connected with STIs.
Search Strategy
The search strategy was constructed to be as inclusive as possible.
Six electronic databases were searched (EMBASE, MEDLINE, ISI
Web of Science, NHS Economic Evaluation Database, Database of
Abstracts of Reviews of Effects, and Health Technology Assess-
ment) up to December 2012 (see Appendix 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.10.007). The
reference lists of potentially relevant articles were then manually
searched to identify additional studies. We used a three-stage
process to identify studies for inclusion, using methods that have
been described in detail elsewhere [51]. Two reviewers initially
F
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into ﬁve groups (A–E) (see Appendix 2 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2013.10.007). Second, two
reviewers read the full texts of potentially relevant studies and
further classiﬁed them (see Appendix 2). Quality assessment
criteria were not applied to exclude studies because so few were
identiﬁed. For each included study, one reviewer extracted data
about the study characteristics, the characteristics of the partic
ipants, the health states examined, the methods and instrument
(s) used, and the results reported and a second reviewer checked
the data. The data were tabulated, and the ﬁndings of individual
studies were compared narratively.ig 1 – Refer to Appendix 2 for explanation of the categorization
TA, Health Technology Assessment; NHS EED, NHS Economic EResults
The electronic database search identiﬁed 6383 published articles,
of which 2001 were duplicates. Figure 1 shows a ﬂow diagram of
the articles identiﬁed, retrieved, and retained or excluded at each
stage and the categorization of the articles.
Nineteen economic evaluations using QALYs were identiﬁed,
and all were included for data extraction. There were 58 articles
that incorporated descriptive measurement of HRQOL for chla-
mydia and associated conditions but only 5 that included
preference-based measurement of such health states.criteria. DARE, Database of Abstracts of Reviews of Effects;
valuation Database.
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Table 1 summarizes the characteristics of the 19 studies. Four
studies included individuals who were considered to be at high
risk of STIs [52–55]. Ten articles examined interventions to
provide chlamydia or gonorrhea screening [52–54,56–62], while
two articles examined different aspects of interventions to treat
or prevent PID [63,64]. Two studies focused on behavioral inter-
ventions [55,65], and one study examined a multifaceted inter-
vention to provide information and increased availability of
testing and treatment [66]. One article was concerned with the
overall costs and “burden of disease” for chlamydia in a particular
country [67], and another article aimed to estimate the lifetime
cost of PID [68]. Two studies examined the effect of expedited
treatment for sexual partners of people with an STI and the effect
of contraceptive use on STI prevention [69,70]. Fifteen studies
presented their results in terms of natural units, for example,
cost per adverse outcome avoided, as well as cost per QALY.
Authors of ﬁve studies applied HSUVs for uncomplicated
chlamydia infection, including cervicitis and urethritis
[52,54,60,61,66]. Most applied HSUVs for one or more named
female reproductive tract complications: PID [52,54,56,59–
67,69,70], ectopic pregnancy [54,56,57,59–66,70], tubal factor infer-
tility [54,56,57,59–66,68], and chronic pelvic pain [52,54,60,61,66].
Fewer studies considered male complications [54,56,59,65–67] or
neonatal complications [56,59,66]. Just over half of the studies
used HSUVs provided by a study by the Institute of Medicine in
the United States [52,56–58,60–64,66,68] although some did not
cite the study directly. Of the remaining evaluations, two studies
[59,69] used values elicited from women with PID from the work
of Smith et al. [71] and one study used the same source but used
values elicited from women without PID [67]. For one cost-
effectiveness study, the source of the utility values was unclear
[55], and the authors of one economic evaluation used a con-
venience sample to generate their own utility values [70].
Although the economic evaluations identiﬁed largely relied on
the same source for HSUVs, there were differences in the actual
values used, the duration over which they were applied, and
around the assumed timing and incidence of sequelae (Table 2).
The base-case values used for chronic pelvic pain varied between
0.6 [57,60–64,66,68] and 0.79 [67] and were applied for durations
ranging from 5 years [54,60–62,65] to the rest of the woman’s life
[67]. For ectopic pregnancy, the values adopted varied between
0.58 [60–64,66] and 1 [57]. For infertility, the utilities included
varied between 0.76 [65] and 0.87 [59]. Most analyzed the uncer-
tainty associated with such values in sensitivity analyses [52,54–
57,59–70], and some found that this had an impact on the results
of the cost-effectiveness analysis [63,65,68], although factors such
as complication and transmission rates were more important.
The majority of the studies did not provide information about the
utility values they adopted (other than the source), and very few
discussed their appropriateness for the population under study.
About half of the studies acknowledged the lack of information
regarding HSUVs, for example, in relation to the limitations
associated with their study [56,59–62,65,67,68,70] (Table 1).
Primary Studies Providing HSUVs for Relevant Health States
Five primary studies valued HRQOL for health states relevant to
chlamydia. Their aims and characteristics are shown in Table 3;
all were based in the United States. The studies provided valu-
ations for a range of relevant health states including PID, chronic
pelvic pain, ectopic pregnancy, and tubal factor infertility.
Pelvic inﬂammatory disease
Three studies generated utility values for PID [71–73]. The values
obtained for PID treatment (Table 4) are difﬁcult to comparebetween studies because each study made different assumptions
about treatment pathways (e.g., inpatient and outpatient care).
Two of these measured both public and patient preferences.
Smith et al. [71] included valuations from women with a history
of PID and women with no experience of this condition. Trent
et al. [72] compared the utilities for health states obtained directly
from adolescents (assumed to give an indication of the views of
patients) and their parents (assumed to represent the views of
the public). One study provided preferences from the perspective
of the public using indirect methods. The study conducted by the
US Institute of Medicine used experts to measure HRQOL using
the Health Utilities Index Mark 2 (HUI-2) and then used the tariffs
associated with this instrument for valuation, which are based on
surveys of the general population [73]. Smith et al. [71] used
visual analogue scale and TTO techniques with a 10-year time
horizon to value all health states directly, and Trent et al. [72]
used visual analogue scale and TTO techniques with a 50-year
time horizon. The health states in the US Institute of Medicine
study were not described in full, but different time horizons were
used for different conditions [73].
Ectopic pregnancy
Utility values for ectopic pregnancy were generated in three
studies [71–73] by using the methods and participants described
earlier. As for PID, the utility values (Table 4) could not be directly
compared between studies because of differing assumptions
made about treatment pathways. The highest utility value for
this condition was generated by parents of adolescents for a
scenario involving a 15-year-old girl experiencing pain and
possibly requiring an operation with the condition resolved in a
few weeks (0.9) [72]. The lowest value was generated for inpatient
treatment for ectopic pregnancy by using the HUI-2 (0.23, with an
expected duration of 3 days), which was followed by outpatient
treatment (0.66 for 4 weeks) [73].
Tubal factor infertility
Four of the primary studies provided utility vales for tubal factor
infertility. Two studies used similar scenarios to generate values
directly, but with different participants and time horizons. Smith
et al. [71] reported lower utility values for women with experience
of PID (0.76) than for women with no experience of PID (0.84),
while Trent et al. [72] reported similar values for adolescents
(0.84) and higher values for their parents (0.91). The Institute of
Medicine’s study reported a utility value of 0.82 by using the HUI-
2 tool; infertility was assumed to last for the woman’s remaining
lifetime [73]. Songer et al. [75] used a scaling method to compare
preferences for infertility against a range of chronic conditions as
they felt that TTO techniques were not suitable for eliciting the
preferences associated with infertility. The authors reported that
infertility was viewed as worse than a chronic headache by 48%
and as worse than paralysis by 12% of the participants. There
were differences in preferences based on experience of previous
pregnancies and the number of children respondents had.
Chronic pelvic pain
Utility values for chronic pelvic pain were reported by four of the
studies. Kuppermann et al. [74] obtained preference values by
using TTO techniques with the patients in their cross-sectional
study of women seeking care for noncancerous pelvic problems.
The women generated a utility value of 0.83 for their pain on the
basis of living for the rest of their lives with their current
symptoms. Smith et al. [71] also provided values from a patient
perspective; women with experience of PID generated a value of
0.69 for pelvic pain compared with a value of 0.79 provided by
women without experience of PID. The description of the health
state used by Smith et al. was slightly different to that adopted in
Table 1 – Summary of characteristics of included economic evaluations.
Lead
author
Evaluation aims Outcomes Perspective Population
targeted by
intervention
and
comparator
Health states
included (for
HSUVs)
Information
presented about
utility values,
including source,
participants,
methods
Sensitivity
analysis
Source
for
HSUVs
QALY MOA
Adams [56] Estimate the cost-
effectiveness of the
National Chlamydia
Screening Strategy and its
alternatives in England
✓ ✓ Health care Men and
women
Epididymitis,
PID, EP, TFI,
NConj,
NPneum
Source cited. Authors
mention the lack of
information available
on utilities
Probabilistic
multivariate
sensitivity
analysis
[73]
Aledort [57] Examine the cost-
effectiveness of gonorrhea
screening in urban
emergency departments
✓ ✓ Societal Women CPP, TFI, EP Source and tool cited Duration & weights
varied in
sensitivity
analysis
[73]
Burgos [55] Evaluate the cost-
effectiveness of a
behavioral intervention
among female sex
workers in Mexico
✓ ✓ Health care High-risk
women
STI, HIV STIs Authors created their
own variable to
modify HRQOL
according to CD4þ
counts
One-, two-, and
multiway
sensitivity
analyses
Unclear
De Vries [58] Estimate the cost-
effectiveness of repeated
screening for Chlamydia
trachomatis at various time
intervals compared with
one-off screening
✓ ✓ Societal Men and
women
Tool and source cited Not reported [73]
Deogan [66] Assess the cost-
effectiveness of a
community-based
intervention to provide
information, and increase
the availability of testing,
treatment, and contact
tracing
✓ ✓ Societal Men and
women
Infection
þsymptoms,
epididymitis,
PID, EP, TFI,
CPP, NConj,
NPneum
Source and tool cited Series of sensitivity
analyses
undertaken
including duration
of 10 y for
sequelae
[73]
Gift [54] Estimate the cost-
effectiveness of screening
men for chlamydia
compared with alternative
strategies
✓ ✓ Societal Men and
women
Infection
þsymptoms,
epididymitis,
PID, EP, CPP,
TFI
Source and previous
study cited
One-, two-, and
multiway
sensitivity
analyses. Sequelae
rate varied in
sensitivity
analysis
[60,73,86]
Gift [69] Evaluate the cost-
effectiveness of expedited
partner therapy compared
with standard partner
✓ Health care
and
societal
Men and
women
PID and
sequelae
Source cited Univariate and
simultaneous
sensitivity
analyses
undertaken
[71,73]
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Table 1 – continued
Lead
author
Evaluation aims Outcomes Perspective Population
targeted by
intervention
and
comparator
Health states
included (for
HSUVs)
Information
presented about
utility values,
including source,
participants,
methods
Sensitivity
analysis
Source
for
HSUVs
QALY MOA
referral for the treatment
of chlamydia or gonorrhea
Gillespie [59] Estimate the cost and cost-
effectiveness of
opportunistic screening
for Chlamydia trachomatis
in Ireland
✓ ✓ Health care Men and
women
Epididymitis,
PID, EP, TFI,
NConj,
NPneum
Source cited.
Limitations of data
included
Probabilistic
sensitivity
analysis
undertaken
[71,73]
Hu [60] Test the cost-effectiveness
of proposed strategies for
chlamydia screening
✓ ✓ Societal Women Infection, PID,
EP, TFI, CPP
Source cited. Authors
mention the need for
further information
on HRQOL for PID and
sequelae
Author states that
utilities were
varied widely in
sensitivity
analysis
[73]
Hu [61] Understand the impact of
different assumptions
about the natural history
of Chlamydia trachomatis
on the cost-effectiveness
of screening strategies
✓ ✓ Societal Women Infection, PID,
EP, TFI, CPP
Source and tool for
utilities given.
Authors mention
limited HRQOL data
available on PID and
sequelae
Author states that a
one-way senitivity
analysis was
undertaken on all
key variables
[73]
Shepherd
[65]
Examine the effectiveness
and cost-effectiveness of
school-based skill-
building behavioral
interventions
✓ ✓ Health care Men and
women
Epididymitis,
PID, EP, TFI,
CPP
Sources, participants,
methods used to
generate utilities
given and lack of
information about
HRQOL for STIs
discussed
QALY losses per STI
case and for
complications
varied in
sensitivity
analysis
[60,71]
Smith [52] Consideration of the effect
of time from STI
acquisition to PID
development on the cost-
effectiveness of different
screening intervals
✓ ✓ Societal High-risk
women
Infection, PID,
PID
complications
Sources given for
utilities
One-way and
multiway
sensitivity
analyses
[73]
Smith [64] Examine the impact of
antibiotic costs on the
cost-effectiveness of PID
therapy for mild to
moderate PID
✓ Societal Women PID, EP,
ruptured EP,
TOA, TFI, CPP
Source and tool used to
generate utilities
given
Utility values varied
over a broad range
in sensitivity
analyses
[73]
Smith [63] Estimate the cost-
effectiveness of
hospitalization compared
with outpatient therapy
for mild to moderate PID
✓ ✓ Societal Women PID, EP,
ruptured EP,
TOA, TFI, CPP
Source, tool, and
participants cited
One-way and
probabilistic
sensitivity
analyses
[73]
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Table 1 – continued
Lead
author
Evaluation aims Outcomes Perspective Population
targeted by
intervention
and
comparator
Health states
included (for
HSUVs)
Information
presented about
utility values,
including source,
participants,
methods
Sensitivity
analysis
Source
for
HSUVs
QALY MOA
Sonnenberg
[70]
Comparison of the cost-
effectiveness of 13
methods of contraception
to no use of contraception
✓ Societal Women PID, EP Some information
about methods used
to elicit utilities using
a convenience
sample. Methods
discussed in relation
to study limitations
Sensitivity analysis,
including omitting
quality-of-life
adjustment
Own
values
Tuite [67] Estimate the burden of
disease and costs of
genital Chlamydia
trachomatis infection in
Canada
✓ ✓ Societal Men and
women
Epididymitis,
PID, PID
complications
Some information
provided on sources
and participants.
Lack of data
mentioned
Deterministic one-
way sensitivity
analysis and
simultaneous
simulation
[71]
Walleser [62] Examine the cost-
effectiveness of a
hypothetical
opportunistic annual
screening program for
chlamydia, compared
with no screening
✓ Health care Women PID, EP, TFI, CPP Source and tool cited One and multiway
sensitivity
analyses
[73]
Wilson [53] Conduct an analysis of the
costs of testing female sex
workers vs. the beneﬁts of
averting transmission of
STIs to clients
✓ ✓ Health care High-risk men Infection þ
complications
Expected value analysis
undertaken to
calculate utility loss
for STIs
Not reported Own
values
Yeh [68] Estimate a range for the
average lifetime cost of
PID and its major
complications
✓ ✓ Societal Women TFI, CPP Details of source given
and limitations in
data mentioned
Author states that
utility values
varied widely in
sensitivity
analysis, state that
there is a lack of
evidence for such
values
[73]
CPP, chronic pelvic pain; EP, ectopic pregnancy; HRQOL, health-related quality of life; HSUV, health state utility value; MOA, major outcome averted; NConj, neonatal conjunctivitis; NPneum,
neonatal pneumonia; PID, pelvic inﬂammatory disease; QALY, quality-adjusted life-year; STI, sexually transmitted infection; TFI, tubal factor infertility; TOA, tubo-ovarian abscess.
* Included different states for PID and EP treatment options.
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Table 2 – Summary of utility values included in economic evaluations, for selected health states.
Lead author Pelvic inﬂammatory disease (PID) Chronic pelvic pain Ectopic pregnancy Tubal infertility
HSUV Dur. Incid. HSUV Dur. Incid. HSUV Dur. Incid. HSUV Dur. Incid.
Aledort [57] 0.6 10 y 0.18 1 1–2 wk 0.08 0.82 10 y 0.2
Deogan [66] OP: 0.63 IP: 10 d 0.84 0.6 30 y 0.165 0.58 4 wk 0.06 0.82 30 y 0.205
0.16IP: 0.57 OP: 2 d
Gift [54] OP: 0.66 10 d 0.34 0.64 5 y 0.18 OP: 0.62
IP: 0.64
IP: 28 d OP: 0.0510 0.84 10 y 0.05
OP: 31 d IP: 0.009IPS: 0.79 12 d 0.0188
IPNS: 0.81 12 d 0.0412
Gillespie [59] 0.992 0.1# 0.076‡ 0.99 0.871 Model run
for 10 y
0.108‡,§
Hu [60] 0.65 11 d 0.4 0.6 5 y 0.18† 0.58 4 wk 0.09 0.82║ Until age 50 y 0.2
Hu [61] 0.65 11 d 0.4 0.6 5 y 0.12¶ 0.58 4 wk 0.04 0.82║ Until age 50 y 0.09
Shepherd [65] 0.9 11 d 0.037# 0.69 5 y 0.019# 0.79 4 wk 0.027# 0.76 15 y 0.067#
Smith [52] 0.65 0.028#
Smith [64] 0.63 0.032 0.6 0.073¶†† 0.58 0.01║ 0.82 0.028║
Smith [63] OP: 0.63 0.032 0.6 0.073¶ 0.58 0.01¶ 0.82 0.028¶
IP: 0.57
Sonnenberg [70] 0.91667 0.01 0.91667 0.005
Tuite [67] AT: 0.87 10 d 0.4 0.79 Remaining lifetime 0.18 0.87 4 wk 0.09 0.84‡‡ Remaining lifetime 0.05
0.08IP: 0.84 2 d
Walleser [62] 0.65 11 d 0.1# 0.6 5 y 0.03 0.58 4 wk 0.012 0.82 Until successful IVF/5 y 0.01
Yeh [68] 0.6 2 y 0.181 0.82 10 y 0.205
Note. Ranges are not shown.
AT, ambulatory treatment; Dur., duration; EP, ectopic pregnancy; HSUV, health state utility value; Incid., incidence; IP, inpatient; IPS, inpatient surgical; IPNS, inpatient nonsurgical; IVF, in vitro
fertilization; OP, outpatient; QALY, quality-adjusted life-year.
* Applied to PID.
† Applied to asymptomatic PID.
‡ Applied to symptomatic PID.
§ Excludes patients with EP.
║ Infertility QALY applied only to 0.25 who receive an infertility workup.
¶ Varied for number of episodes of acute PID.
# Applied to positive cases of chlamydia infection.
** Recurrent PID.
†† Applied to post-PID health state.
‡‡ Applied to women with infertility workup.
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Table 3 – Included primary studies with utility values.
Lead author Study aims Participants Number of
participants
Techniques
used
Health states valued Direct/
indirect
valuation
Further information on
methods
Kuppermann
[74]
Assess the impact
of abnormal
uterine bleeding
and pelvic pain
and pressure on
HRQOL and
sexual
functioning
Women seeking
care for
noncancerous
pelvic problem
(aged 31–54 y)
By symptoms:
Pain only ¼ 272
TTO Pelvic pain, pain and bleeding,
heavy bleeding with/without
leiomyomata, ﬁbroids with
pressure
Direct In an interview setting, patients
asked how many years of their
remaining lives they would be
willing to give up to live
without the symptoms they
were experiencing
Pain and bleeding
¼ 278
Heavy bleeding
without
leiomyomata ¼
190
Heavy bleeding
with
leiomyomata ¼
570
Fibroids with
pressure ¼ 183
Smith [71] Measure quality-
of-life utilities
for health states
associated with
PID
Women with/
without a
history of PID
(aged 18þ y)
By disease
history: PID: 56
TTO; VAS PID OP, PID IP, ectopic pregnancy,
infertility, chronic pelvic pain
Direct Participants read scenarios to
describe health states and then
used a computerized tool to
give VAS and TTO valuations
for health states using. Subjects
were asked to trade-off
between living 10 y in the
health state and varying
amounts of time in full health
No PID: 150
Songer [75] Identify the value
that women
with PID assign
to the impact of
future infertility
on health
Women with
signs and
symptoms of
PID
By pregnancy
history: 0 live
births ¼ 205
Other* Infertility Direct Women with PID were asked to
rate whether life with infertility
was more or less meaningful
than life with a series of 7
chronic conditions
1 live birth ¼ 168
2 live births ¼ 90
3 or more live
births ¼ 68
Institute of
Medicine
[73]
Develop a
quantitative
model to
prioritize the
development of
vaccines for
infectious
diseases
Experts and
members of
committee
Expert committee
members
Other Acute urethral syndrome,
cervicitis/bartholinitis, PID OP,
PID IPNS, IPS, OPAIP, ectopic
pregnancy (IP/OP), infertility,
chronic pelvic pain, Reiter's
syndrome, arthritis, urethritis,
epididymitis (OP/IP)
Indirect A committee to study priorities
for vaccine development
developed scenarios for health
conditions with input from
experts. These scenarios were
used to complete the HUI2 tool,
which enabled utilities to be
calculated
Trent [72] Investigate and
compare
Adolescents
(aged 12–19 y)
TTO; VAS PID OP, PID IP, ectopic pregnancy,
infertility, chronic pelvic pain
Direct Adolescent girls and parents
completed a Web-based survey
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 1 6 – 1 3 0 125the study by Kuppermann et al. because it was stated that the
pain may go away. Trent et al. used a scenario similar to that of
Smith et al., but the subject was a 15-year-old girl and a 50-year
time horizon was used within the TTO exercise. While adoles-
cents gave a value of 0.76 for this health state, their parents
reported a slightly higher value of 0.85 [72]. The study by the
Institute of Medicine generated an HUI-2 value of 0.60, and the
condition was assumed to last for the remainder of the woman’s
life [73].Discussion
This systematic review found 19 published economic evaluations
about chlamydia infection and associated sequelae that reported
outcomes as cost per QALY. Half of the articles used the same
source for HSUVs, but several applied modiﬁed values or altered
the duration for which they were applied. Half of the economic
evaluations mentioned some difﬁculties associated with valuing
the health states for chlamydia. Most studies analyzed the
uncertainty around HSUV estimates for the state of infection
and its sequelae through a sensitivity analysis, but none dis-
cussed in detail the implications associated with the primary
research informing their HSUV estimates. There were ﬁve pri-
mary studies that provided HSUVs for health states relevant to
chlamydia infection; all but one used direct methods to value
health states.
As for many infectious diseases, understanding the impact of
chlamydia on HRQOL involves assessing the nature and epidemi-
ology of the sequelae and our ability to link them back to
infection. In the majority of the economic evaluations, limita-
tions around our understanding of HRQOL for the health states
associated with chlamydia and its sequelae were not fully
explored and the ways in which health states had been con-
ceptualized and valued were not discussed in detail. For example,
the primary studies demonstrated that health states were valued
very differently depending on the characteristics of the research
participants (e.g., patients or public), but the economic evalua-
tions reviewed did not discuss the implications associated with
the values they adopted. In economic evaluations of diseases in
which the primary evidence is limited, balancing the need to
adequately reﬂect the decision problem and disease processes
against the availability and quality of data can be problematic
[12]. While the economic evaluations have clearly attempted to
tackle the complexities involved in understanding the effects of
interventions in this area, we believe that it is imperative that
such studies fully convey the limitations in our knowledge about
the sequelae of chlamydia and about preference-based HRQOL for
these conditions, to ensure that decision makers are fully
informed and to emphasize the importance of further primary
research to inform such economic analyses.
None of the utility values reported in the primary studies we
identiﬁed could be used without reservation to inform economic
evaluations in the United Kingdom. When selecting HSUVs from
the literature, it is important to consider both the methods used
to generate the values and their relevance to the population
under consideration [4]. In this instance, the methods used in the
primary studies would need to be considered against the “refer-
ence case” methods for estimating cost-effectiveness set out by
NICE, which recommends that HRQOL be measured directly by
patients or their carers and that these measurements be valued
by a representative sample of the general population by using a
choice-based method [15]. The study by the Institute of Medicine
relied on expert views to measure HRQOL, which is generally
seen as less preferable than measuring patient experiences of
health states directly [4]. The remaining studies used scenarios to
value HRQOL rather than direct patient measurement. There
Table 4 – Utility values provided by primary studies.
Health state Lead author Result Duration Further information about the
health states valued
PID Institute of
Medicine
[73]
HUI value Utilities were
calculated by
using HUI-2
PID outpatient treatment was
assumed to last for 10 d and
inpatient treatment for 2 d
Outpatient only: 0.63
IPNS: 0.57
IPS: 0.46
OPAIP: 0.83
Smith [71] Outpatient treatment 10-y time horizon
for all states
The outpatient scenario involved a
25-y-old woman with pain for
about 7 d (affecting usual
activities) and antibiotic
treatment for 14 d. It is stated
that the woman has a very small
chance of developing
complications and a chance of
getting PID again in the future.
The inpatient scenario involved a
hospital stay for 2–3 d with
antibiotics by vein and antibiotic
pills for a further 11–12 d at
home. It is explained that
complications are more likely
when the illness requires
hospital treatment
TTO mean value  SD
 Women with PID: 0.90  0.22
 Women without PID: 0.87
 0.26
Inpatient treatment
TTO mean value  SD
 Women with PID: 0.82  0.29
 Women without PID: 0.84
 0.27
Trent [72] Outpatient treatment 50-y time horizon
for all states
Scenario involved a 15-y-old girl
with an adapted version of the
approach adopted by Smith et al.
[71]
TTO mean value  SD
 Parents: 0.90  0.27
 Adolescents: 0.82  0.33
 Inpatient treatment
 TTO mean value  SD
 Parents: 0.88  0.30
 Adolescents: 0.78  0.36
Chronic
pelvic pain
Kuppermann
[74]
TTO mean value  SD Full remaining life 72.5% women seeking care for
noncancerous pelvic problems
experienced pain, 71%
experienced bleeding
 Pain only: 0.83  0.01
 Pain and bleeding: 0.78 
0.02
Smith [71] TTO mean value  SD 10-y time horizon
for all states
Scenario used to value health states
involved a 25-y-old woman with
pain that may slowly go away or
could stay the same
 Women with PID: 0.69  0.37
 Women without PID: 0.79
 0.29
Institute of
Medicine
[73]
HUI value Utilities were
calculated by
using HUI-2
Consequences of PID assumed to
have a 5-y lag from infection.
Chronic pelvic pain assumed to
last for remaining lifetime and
affect 3% of infected women
0.60
Trent [72] TTO mean value  SD 50-y time horizon
for all states
Scenario involved a 15-y-old girl
with an adapted version of the
approach adopted by Smith et al.
[71]
 Parents: 0.85  0.31
 Adolescents: 0.76  0.38
Tubal
infertility
Smith [71] TTO mean value  SD 10-y time horizon
for all states
Scenario involves a 25-y-old
woman who has been trying to
get pregnant for 1 y but has been
unable to do so
 Women with PID: 0.76  0.34
 Women without PID: 0.84
 0.29
Songer† [75] % rating infertility as worse
than:
Scenario suggests
that infertility
would last for
remaining
lifetime
All the women had signs and
symptoms of PID. They were
asked to give their own
preferences for infertility
compared with other health
states. Infertility deﬁned as “you
would not be able to become
pregnant or bear children”
Sinus congestion
 All women: 48
 Women with no children: 76
Chronic headache
 All women: 65
 Women with no children: 62
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Table 4 – continued
Health state Lead author Result Duration Further information about the
health states valued
Paralysis
 All women: 12
 Women with no children: 18
Institute of
Medicine
[73]
HUI value Utilities were
calculated by
using HUI-2
Consequences of PID assumed to
have a 5-y lag from infection.
Tubal infertility assumed to last
for remaining lifetime and affect
3.3% of infected women
0.82
Trent [72] TTO mean value  SD 50-y time horizon
for all states
Scenario involved a 25-y-old
woman with an adapted version
of the approach adopted by
Smith et al. [71]
 Parents: 0.91  0.25
 Adolescents: 0.84  0.32
Ectopic
pregnancy
Smith [71] TTO mean value  SD 10-y time horizon
for all states
Scenario involved a 25-y-old
woman with an ectopic
pregnancy requiring a range of
treatment options. She was
described as experiencing pain
and possibly needing an
operation, but it was stated that
life would return to normal in a
few weeks
 Women with PID: 0.79  0.34
 Women without PID: 0.87
 0.26
Institute of
Medicine
[73]
HUI value Utilities were
calculated by
using HUI-2
All consequences of PID assumed to
have a 5-y lag from infection.
Duration of 4 wk assumed for
outpatient treatment for ectopic
pregnancy, 3 d for inpatient
treatment
 0.58 (outpatient only)
 0.23 (inpatient) þ
 0.66 (OPAIP)
Trent [72] TTO mean value  SD 50-y time horizon
for all states
Scenario involved a 15-y-old girl
with an adapted version of the
approach adopted by Smith et al.
[71]
 Parents: 0.91  0.26
 Adolescents: 0.82  0.35
Note. A glossary of the instruments/techniques cited that measure and value the health-related quality of life is provided in Appendix 3.
HUI-2, health utilities index 2; IPNS, inpatient nonsurgical; IPS, inpatient surgical; OPAIP, outpatient after inpatient; PID, pelvic inﬂammatory
disease; TTO, time trade-off; VAS, visual analogue scale.
* VAS values are not reported in this table.
† Songer et al. [75] used a quasi-rating scale preference measure using paired comparisons to obtain the value participants assigned to future
fertility.
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studies. The study by Kuppermann et al. provided values based
on the speciﬁc symptoms the women with pelvic problems were
experiencing, and the studies by Smith et al. and Trent et al. were
carried out in areas of high STI prevalence in the United States,
which would not apply to the UK general population.
Infectious diseases and their sequelae offer an intriguing lens
through which to analyze methodological debates about how we
should measure and value the beneﬁts of health care, enabling
exploration of key questions such as how should HRQOL be des-
cribed and measured, how should it be valued, and whose values
should be taken into account [5]. For chlamydia, it is difﬁcult to
measure patient-reported HRQOL directly because sequelae
can happen a long time after the initial infection and cannot be
etiologically linked. This means that most primary studies to date
have used direct valuation methods using descriptions of health
states. Direct valuation methods, however, are seen as less robust,
because there is no clear link to patient-reported HRQOL [4]. For
conditions in which it is difﬁcult to measure preferences indirectly,
there is a need for further discussion about the most effective ways
to elicit utility values to inform economic evaluations [76]. There is
a growing body of research examining the impact of stigma onHRQOL in relation to STIs and other conditions [77–80], and there
have been attempts to include the effects of stigma in the valua-
tion of health states [81], but further exploration of such issues is
needed.
Infectious diseases such as chlamydia involve combinations of
short- and long-term health states. There is evidence that prefer-
ences for health states may be partly affected by their duration,
and there is ongoing debate about how we overcome such
problems [44,82]. There is also discussion about how we incorpo-
rate time preference within valuations of health states, which is
pertinent to research involving chlamydia and other diseases, in
which complications may occur or be detected many years after
the initial infection [46,83]. The primary studies we identiﬁed
demonstrated that different values were obtained for different
groups of participants, which has implications for broader meth-
odological discussions about whose preferences should be used to
value health states [47,48]. This issue is particularly important for
STIs because of the asymmetry between men and women in the
burden associated with the complications of disease, even though
both sexes acquire and transmit the infection itself.
We identiﬁed two previous systematic reviews focusing on
outcomes for economic evaluations relating to chlamydia
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 1 6 – 1 3 0128infection. Roberts et al. [17] reviewed economic evaluation and
modeling studies in this area published up to 2004. Approxi-
mately half of the studies reviewed used “cost per case detected”
as the main outcome. This is not an appropriate base for policy
decisions because these are only surrogate end points and do not
determine the success of the intervention for chlamydia. The
current review shows that the use of cost per QALY has increased
markedly, possibly as a reﬂection of the impact of recommenda-
tions made by NICE, the Pharmaceutical Beneﬁts Advisory Com-
mittee in Australia. and other decision-making bodies [15,16,84]. A
second review described alternative approaches to measure and
value the quality of life associated with the sequelae of chlamydia
and considered studies up to the end of 2011 [85]. The authors
concluded that it was not possible to reach ﬁrm conclusions about
the most appropriate techniques for measuring HRQOL and valuing
outcomes for chlamydia. The current review examines how HSUVs
have been used within economic evaluations, and it critically
examines the primary data available to inform cost-effectiveness
studies, based on a wide range of search terms.
Strengths and Limitations
The main strength of this study is that it provides a comprehen-
sive overview of economic evaluations about chlamydia infection
that have reported their results in terms of cost per QALY.
Another strength is the critical appraisal of HSUVs that have
been used in existing economic evaluations alongside a consid-
eration of the wider primary evidence on HSUVs and associated
methodological issues. There are also weaknesses associated
with this review. Some studies were not explicit in stating that
the condition under study was associated with chlamydia. Hence,
reviewers had to use their judgment to determine which studies
should be included and might have incorrectly included or
excluded relevant publications. Another weakness relates to the
different methods that have been used to value HRQOL, which
makes it difﬁcult to make comparisons between studies and
reach conclusions on the differences between them.Conclusions
There is limited information about HSUVs associated with chla-
mydia infection and its complications, which has implications for
the robustness of economic evaluations in this area. Future
economic evaluations need to be ﬁrmly rooted in our under-
standing of the natural history of the disease and its sequelae
and fully discuss any limitations associated with the underlying
evidence, to ensure that decision makers are as informed as
possible and to inform future research agendas. To be in line with
generic NICE guidelines for economic evaluations, future
research is needed to understand preferences for health states
associated with chlamydia. We would argue that such research
needs to fully engage with wider methodological debates about
how we measure and value health states. The valuation of health
states for chlamydia and other infectious diseases can be partic-
ularly challenging because it may not be possible to use the
methods that are generally viewed to be the most robust. For
example, complications may occur many years after the initial
infection and cannot be etiologically linked, which means that
direct measurement of patient-reported HRQOL and the applica-
tion of indirect valuation methods are not possible. Thus, there
needs to be further exploration of the most appropriate methods
of value elicitation to use in different settings, to ensure the best
match of methods to the aims of the research [76]. In addition,
further exploration is required around methods for valuing and
combining preferences for health states of varying duration and
occurring over different time horizons. Issues relating to themeasurement and valuation of the effects of stigma, and debates
about whose preferences count, also need to be examined in
greater depth. Unless we adequately tackle the challenges asso-
ciated with measuring and valuing HRQOL for chlamydia and
other infectious diseases, evaluating the cost-effectiveness of
interventions in this area will remain problematic.Acknowledgments
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